Announcement on Voluntary Disclosure of Completion of the First Patient Enrollment and Dosing in the Phase II Clinical Trial of SGC001 Innovative Drug by a Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment